Lumakras A Big Focus For Amgen; More Data Coming Soon

KRAS Inhibitor’s Q2 Sales Lumped In With ‘Other’ Products

 
• By Mandy Jackson
  
Amgen logo sign hanging on the office building in Rotkreuz, Switzerland
Lumakras monotherapy updates and the first combo results will be reported over the next year • Source: Alamy

More from Earnings

More from Business